RxDoctor Payments Data

Macey Seibel, PA

Medical · Cleveland, OHNPI 1437747284

Payments from drug & device makers

$858in general payments, 2019–2025

Across 27 payments — averaging $31.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$552
  • Convatec Inc.$99
  • Sumitomo Pharma America, Inc.$75
  • AbbVie$62
  • 180 Medical, Inc.$29
  • BD$21
  • plus $20 from 1 others

What the payments were for

  • Food & beverage$858100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic15$552
Convatec Inc.5$99
Sumitomo Pharma America, Inc.1$75
AbbVie3$62
180 Medical, Inc.1$29
BD1$21
Axonics, Inc.1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$858 in reported general payments places this provider in the 65th percentile of 547 medical providers in Ohio.

See all medical providers in Ohio

Medicare billing

Part B allowed, 2024
$35,155
Medicare patients
369
Services billed
734

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron310$225,771
GemtesaVibegron135$94,903
Trospium Chloride326$20,781
Mirabegron ErMirabegron21$16,215
Estradiol174$12,496
Methenamine Hippurate153$9,705
Trospium Chloride ErTrospium Chloride48$5,702
Tamsulosin Hcl277$4,100
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst158$2,989
NitrofurantoinNitrofurantoin Macrocrystal58$1,992
Tolterodine Tartrate ErTolterodine Tartrate17$1,917
Alfuzosin Hcl ErAlfuzosin Hcl78$1,682
Solifenacin Succinate53$1,425
Finasteride128$1,269
Cephalexin211$894

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$75$94,903135 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 547 medical providers in Ohio.

Other medical in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →